Advances in understanding and treating cardiac cachexia: Highlights from the 5th cachexia conference

International Journal of Cardiology

Volumn 144, Issue 3, 2010, Pages 347-349

  Von Haehling, Stephan ^a,b   Stepney, Rob ^d   Anker, Stefan D ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d NONE

Author keywords

Cachexia; Heart failure; Pathophysiology; Therapy

Indexed keywords

ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR 2B; ANABOLIC AGENT; BISOPROLOL; CARDIAC AGENT; CELECOXIB; CK 2017357; GHRELIN; IMIDAPRIL; MELANOCORTIN RECEPTOR AGONIST; MT 102; MYOSTATIN; PLACEBO; SNT 207979; SUN 11031; TESTOSTERONE; UNCLASSIFIED DRUG;

ANOREXIA; CACHEXIA; CARDIAC CACHEXIA; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG MECHANISM; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

EID: 77957886583     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.05.042     Document Type: Editorial

References (13)

1. W.J. Evans, J.E. Morley, J. Argilés, C. Bales, V. Baracos, and D. Guttridge Cachexia: a new definition Clin Nutr 27 2008 793 799
2. S. von Haehling, M. Lainscak, J. Springer, and S.D. Anker Cardiac cachexia: a systematic overview Pharmacol Ther 121 2009 227 252
3. S.D. Anker, P. Ponikowski, S. Varney, T.P. Chua, A.L. Clark, and K.M. Webb-Peploe Wasting as independent risk factor for mortality in chronic heart failure Lancet 349 1997 1050 1053
4. R.J. Skipworth, G.D. Stewart, C.H. Dejong, T. Preston, and K.C. Fearon Pathophysiology of cancer cachexia: much more than host-tumour interaction? Clin Nutr 26 2007 667 676
5. K. Kalantar-Zadeh, N. Kuwae, D.Y. Wu, R.S. Shantouf, D. Fouque, and S.D. Anker Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients Am J Clin Nutr 83 2006 202 210
6. B.R. Celli, C.G. Cote, S.C. Lareau, and P.M. Meek Predictors of survival in COPD: more than just the FEV1 Respir Med 102 Suppl 1 2008 S27 S35
7. T. Kung, J. Springer, W. Doehner, S.D. Anker, and S. von Haehling Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference Expert Opin Investig Drugs 19 2010 579 585
8. M. Muscaritoli, S.D. Anker, J. Argilés Z. Aversa, J.M. Bauer, and G. Biolo Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics" Clin Nutr 29 2010 154 159
9. S. von Haehling, S. Genth-Zotz, S.D. Anker, and H.D. Volk Cachexia: a therapeutic approach beyond cytokine antagonism Int J Cardiol 85 2002 173 183
10. S.D. Anker, and A.J. Coats Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation Chest 115 1999 836 847
11. S.D. Anker, P. Lechat, and H.J. Dargie Prevention and reversal of cachexia in patients with chronic heart failure by bisoprolol: results from the CIBIS II-study J Am Coll Cardiol 41 2003 156A 157A Abstract
12. D. Langin Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome Pharmacol Res 53 2006 482 491
13. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150